Via Exclusive OTC Markets Release:

Date: October 6, 2015

EP Global Communications, Inc.
Management's Discussion of Annual Report
Fiscal Year End June 30, 2015

Today, it can be reported that EPGL has made tremendous advancements with its technologies since this same time in 2014. The goal of seeing the companies advanced technologies being commercialized by one or more major companies appears to be very well on track. Technologies have been invented, experiments have been conducted and now IP is being prosecuted on several of EPGL's technologies, we are happy to report. EPGL management believes that our growth as a Company is just at the beginning stages.

EP Global Communications, Inc. (EPGL) continues to build its business as an advanced research and development company, specializing in microelectronic mechanical systems for ophthalmic, medical and wearable consumer electronic devices. In 2012, EPGL was restructured into a medical device company initially and then pivoted its business model exclusively into research and development in 2013 when CooperVision, Inc. approached the Company and signed it to a Development Agreement involving the creation of advanced ophthalmic technologies for integration of microelectronics into modern, silicone hydrogel contact lenses. It is believed by several top technology CEO's and analysts, that the electronic augmentation and enhancement of vision applications will generate several billion dollars of new revenue in the field of ophthalmic, medical and consumer electronics within the next several years.

Since 2013 and most notably, since the 2014 Annual report, EPGL has now successfully progressed several provisional patents pending into

non-provisional and PCT application filings status as projected during 2014 and 2015. This was achieved after extensive project work and consultation with CooperVision R&D involving onsight materials delivery and experimentation by CooperVision researchers for proof of concept. After seeing the successful results of the solutions created and achieved by EPGL, CooperVision, Inc. moved forward for Intellectual Property prosecution with EPGl into 2015. These patents continue to be filed to the present day. As was reported earlier in 2015, EPGL rebuffed an effort by CooperVision to have a exclusive Option to License EPGL technology several months earlier than anticipated.
The significance of the technologies which EPGL and CooperVision have been engaged is that they involve discoveries and breakthroughs in the integration of microelectronics into modern silicone hydrogel contact lenses. This is very important as any successfully commercialized contact lenses containing electronic augmentation or vision enhancements in the future, will need to be comfortable, safe and mass manufactured. EPGL believes that some of the technologies it has developed with CooperVision are leading in the field and have potential to block other companies within the field from achieving the same successful integration of electronics into mass manufactured contact lenses without negotiation of royalties and compensation to EPGL and CooperVision.

EPGL and CooperVision continue to negotiate terms and settlement of a License Royalty Agreement to adequately compensate EPGL commercialization of the joint technologies going forward, by CooperVision and/or its affiliates. EPGL believes that a successful resolution to the the negotiations can occur literally at anytime without notice. However, EPGL investors should also be aware that should EPGL management not be satisfied with the results of present negotiations with CooperVision, that EPGL intends to protect the interests of the company and shareholders, even if that means litigation.

As previously disclosed in early 2015, EPGL and AT&T have jointly developed new art within the consumer, military and corporate

wearables space, which EPGL is developing IP for prosecution. All previously announced Agreements with other Corporations remain in effect according to their individual terms and EPGL intends to exploit those terms to the benefit of the Company going forward.

In summary, EPGL started in earnest in 2014 within this new field of advanced research and development of technologies and is a start-up company with all the inherent risks and rewards possible. It is possible that the USPTO could deny one or more of our pending patents for approval. On the other hand, it is also possible that one or more of EPGL's patents will be successfully granted. Each passing day brings EPGL closer to the answers to these questions. EPGL management continues to believe that the Company has tremendous growth potential moving forward based on the technologies it has developed and the market potential for such technologies as corroborated by the opinions of other major market players in the field. The Company wishes to thank our long shareholders for their support and management believes that all present shareholders are part of EPGL at the right time in its history. EPGL pledges to continue to advance new technologies and relationships with top corporations in the field.

Investors should consider all the risks and rewards associated with a high level technology company start-up with multiple patents pending, such as EPGL, prior to investing.

About EP Global Communications, Inc.

EP Global Communications, Inc. is an advanced technology development company for both medical devices and consumer electronics devices specializing in microelectronic mechanical systems (MEMS).

Safe Harbor Statement

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.